Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.52 |
| ▸ | GRM5 | P41594 | 10/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025087 | 1.00 | PDK4 (0.54) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL2422977 | 0.89 | PDK4 (0.57) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL17655532 | 0.84 | PDK4 (0.61) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL2491264 | 0.84 | PDE10A (0.61) | PDK4GRM1GRM5PDE10AJAK1 | |
| SCHEMBL16112803 | 0.83 | PDK4 (0.61) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL19092559 | 0.83 | PDK4 (0.58) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL5749286 | 0.82 | HTR6 (0.52) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL15951022 | 0.81 | PDK4 (0.60) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL30676170 | 0.81 | GRM5 (0.61) | PDK4GRM1GRM5PDE10AHTR6 | |
| SCHEMBL2631187 | 0.81 | GRM5 (0.61) | PDK4GRM1GRM5PDE10AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309013-A1 | SYNTHESIS OF 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118251396-A | Synthesis of 2' - (7, 7-dimethyl-1 ' H, 7H-spiro [ furo [3,4-b ] pyridin-5, 4' -piperidin ] -1' -yl) -1, 3-dihydro-4'H-spiro [ indene-2, 5' - [1,3] oxazol ] -4' -one and crystalline forms thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023088996-A1 | SYNTHESIS OF 2'-(7,7-DIMETHYL-1'H,7H-SPIRO[FURO[3,4-B]PYRIDINE-5,4'-PIPERIDIN]-1'-YL)-1,3-DIHYDRO-4'H-SPIRO[INDENE-2,5'-[1,3]OXAZOL]-4'-ONE, AND CRYSTALLINE FORMS THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309013-A1 | SYNTHESIS OF 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one | HTR2C, HTR1A, HTR1B | PDK4 184/4885GRM1 59/4885GRM5 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.